Dr. Warren R. Abel, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of South Florida College of Medicine (1985)
- Years since graduation
- 41
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 375
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1985Medical school: University of South Florida College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
FL license ME62909 -
Critical Care Medicine (Internal Medicine) Physician
FL license ME62909
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Josephs Hospital Tampa, FL
- Morton Plant Hospital Clearwater, FL
- Mease Countryside Hospital Safety Harbor, FL
- St Anthonys Hospital Saint Petersburg, FL
- Orlando Health Bayfront Hospital Saint Petersburg, FL
Medical groups
- Coastal Pulmonary and Critical Care PLC (9 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 375
- Services billed
- 1,055
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 462 | 175 |
| Established patient office or other outpatient visit, 30-39 minutes | 374 | 205 |
| Critical care, first 30-74 minutes | 174 | 81 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 64 | 62 |
| Test to examine how well the lungs exchange gases | 58 | 57 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 58 | 57 |
| Test to determine lung volumes using sensors | 57 | 56 |
| New patient office or other outpatient visit, 60-74 minutes | 22 | 22 |
| Established patient office or other outpatient visit, 40-54 minutes | 21 | 19 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in St Petersburg, FL | 202 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in St Petersburg, FL | 158 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in St Petersburg, FL | 125 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in St Petersburg, FL | 70 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in St Petersburg, FL | 69 |
| Prednisone Other prescribers in St Petersburg, FL | 56 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in St Petersburg, FL | 49 |
| Ventolin Hfa (albuterol sulfate) Other prescribers in St Petersburg, FL | 46 |
| Azithromycin Other prescribers in St Petersburg, FL | 45 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in St Petersburg, FL | 34 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 92 payments worth $2,278 in total to this clinician.
| GlaxoSmithKline, LLC. | $440 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $388 |
| Insmed, Inc. | $253 |
| Regeneron Healthcare Solutions, Inc. | $148 |
| Genzyme Corporation | $117 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $98.35 |
| United Therapeutics Corporation | $96.46 |
| Merck Sharp & Dohme LLC | $89.79 |
| Food and Beverage | $2,261 |
|---|---|
| Education | $17.38 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Insmed, Inc. Aug 15, 2025 | Education in-kind | $17.38 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $149,536 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
E.r. Squibb & Sons, L.l.c. - The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
AstraZeneca Pharmaceuticals LP - A prospective, real-world, interventional study to evaluate the effect
GlaxoSmithKline, LLC. - Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04701983 - A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.